No Prescription |
 |
 | ||
|
CoAprovel Avalide |
|
| ||
No Prescription » Prescription Drugs 4 » CoAprovel Avalide This drug is used to treat high blood pressure (hypertension). This medication is a combination of two drugs (an angiotensin receptor blocker and a thiazide "water pill"/diuretic). Irbesartan blocks the hormone angiotensin thereby relaxing blood vessels causing them to widen. The thiazide diuretic increases the amount of urine you make therefore decreasing excess water and salt in your body. High blood pressure reduction helps prevent strokes heart attacks and kidney problems. Buy CoAprovel Avalide and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About CoAprovel Avalide: Product Type: Prescription Drugs 4 CoAprovel ( Avalide Generic Irbesartan ) CoAprovel (Avalide Generic Irbesartan) Avalide Generic Irbesartan 150/12.5mg 14 Tablets 150/12.5mg 42 (3 x 14 Tablets) 150/12.5mg 84 (6 x 14 Tablets) 300/12.5mg 14 Tablets 300/12.5mg 84 (6 x 14 Tablets) 300/12.5m 42 (3 x 14 Tablets) Avalide Generic Irbesartan CoAprovel
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
